- ►prsjournal.com J Raftery, A Clegg, J Jones, SC Tan, A Lotery - British Journal of Ophthalmology, 2007 - bjo.bmj.com Two new drugs provide startling benefits in the treatment of age-related macular
degeneration (AMD). The clinical and cost effectiveness of ranibizumab
(Lucentis) was compared to that of bevacizumab (Avastin), which costs up to ... Cited by 38 - Related articles - BL Direct - All 6 versions
- ►129.237.146.186 [PDF] H Kourlas, DS Schiller - Clinical therapeutics, 2006 - Elsevier Only 1 research group has evaluated the tolerability and efficacy of pegaptanib
in patients with neovascular ARMD. The VEGF Inhibition Study in Ocular
Neovascularization involved 2 concurrent randomized trials of intravitreous ... Cited by 36 - Related articles - All 4 versions
GC Brown, MM Brown, J Campanella, GR … - American journal of ophthalmology, 2005 - Elsevier Five-year visual acuity data from the TAP (Treatment of Age-related Macular
Degeneration With Photodynamic Therapy) Investigation were modeled into a
12-year, value-based, reference case, cost-utility model utilizing year ... Cited by 34 - Related articles - All 5 versions
G Kobelt, B Jonsson, A Bergstrom, E Chen, C … - Acta Ophthalmologica Scandinavica, 2006 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 21 - Related articles - BL Direct - All 2 versions
- ►adisonline.com [PDF] J Wickens, KJ Blinder - Drug safety, 2006 - ingentaconnect.com The prevalence of neovascular age-related macular degeneration (AMD) is Abstract
expected to increase significantly during the next 20 years. New treatment
alternatives to laser photocoagulation are on the horizon – the first of ... Cited by 10 - Related articles - BL Direct - All 6 versions
G Donati - Ophthalmologica, 2007 - content.karger.com The cornerstone of pharmacotherapeutic treatment for age-related macular
degeneration (AMD) is photodynamic therapy with verteporfin. The recently
approved pegaptanib sodium, which targets vascular endothelial growth ... Cited by 9 - Related articles - BL Direct - All 4 versions
M Zarbin - Archives of Ophthalmology, 2006 - archopht.highwire.org You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Add to CiteULike Add to ... Cited by 10 - Related articles - BL Direct - All 3 versions
N Bansback, S Davis, J Brazier - Eye, 2006 - nature.com A health economic model is used to synthesise the evidence on contrast
sensitivity and treatment rates from the TAP Investigation with health state
utilities and costs. Impairment of visual function is estimated using a ... Cited by 11 - Related articles - BL Direct - All 3 versions
- ►adisonline.com [PDF] JK Schmier, ML Jones, MT Halpern - Pharmacoeconomics, 2006 - ingentaconnect.com As age-related macular degeneration (AMD) becomes more prevalent as a Abstract
result of longer life expectancy and the number of elderly people worldwide, it
will become increasingly important to understand its potential health and ... Cited by 8 - Related articles - BL Direct - All 7 versions
